1141 related articles for article (PubMed ID: 19242475)
41. Gain-of-function mutations in protein kinase Cα (PKCα) may promote synaptic defects in Alzheimer's disease.
Alfonso SI; Callender JA; Hooli B; Antal CE; Mullin K; Sherman MA; Lesné SE; Leitges M; Newton AC; Tanzi RE; Malinow R
Sci Signal; 2016 May; 9(427):ra47. PubMed ID: 27165780
[TBL] [Abstract][Full Text] [Related]
42. A PDK-1 allosteric agonist neutralizes insulin signaling derangements and beta-amyloid toxicity in neuronal cells and in vitro.
Querfurth H; Marshall J; Parang K; Rioult-Pedotti MS; Tiwari R; Kwon B; Reisinger S; Lee HK
PLoS One; 2022; 17(1):e0261696. PubMed ID: 35061720
[TBL] [Abstract][Full Text] [Related]
43. Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta}.
Zhao WQ; Lacor PN; Chen H; Lambert MP; Quon MJ; Krafft GA; Klein WL
J Biol Chem; 2009 Jul; 284(28):18742-53. PubMed ID: 19406747
[TBL] [Abstract][Full Text] [Related]
44. Roles of astrocytes and prions in Alzheimer's disease: insights from mathematical modeling.
Maji M; Khajanchi S
J Biol Phys; 2024 Jun; 50(2):149-179. PubMed ID: 38157152
[TBL] [Abstract][Full Text] [Related]
45. Neuronal α-amylase is important for neuronal activity and glycogenolysis and reduces in presence of amyloid beta pathology.
Byman E; Martinsson I; Haukedal H; ; Gouras G; Freude KK; Wennström M
Aging Cell; 2021 Aug; 20(8):e13433. PubMed ID: 34261192
[TBL] [Abstract][Full Text] [Related]
46. Noninvasive Antemortem Detection of Retinal Prions by a Fluorescent Tracer.
Aguilar-Calvo P; Sevillano AM; Rasool S; Cao KJ; Randolph LM; Rissman RA; Sarraf ST; Yang J; Sigurdson CJ
J Alzheimers Dis; 2022; 88(3):1137-1145. PubMed ID: 35754278
[TBL] [Abstract][Full Text] [Related]
47. Single molecule characterization of the interactions between amyloid-β peptides and the membranes of hippocampal cells.
Narayan P; Ganzinger KA; McColl J; Weimann L; Meehan S; Qamar S; Carver JA; Wilson MR; St George-Hyslop P; Dobson CM; Klenerman D
J Am Chem Soc; 2013 Jan; 135(4):1491-8. PubMed ID: 23339742
[TBL] [Abstract][Full Text] [Related]
48. Correlative cryo-soft X-ray tomography and cryo-structured illumination microscopy reveal changes to lysosomes in amyloid-β-treated neurons.
Marshall KE; Mengham K; Spink MC; Vania L; Pollard HJ; Darrow MC; Duke E; Harkiolaki M; Serpell LC
Structure; 2024 May; 32(5):585-593.e3. PubMed ID: 38471506
[TBL] [Abstract][Full Text] [Related]
49. Targeting epigenetic mechanisms in amyloid-β-mediated Alzheimer's pathophysiology: unveiling therapeutic potential.
Li JZ; Ramalingam N; Li S
Neural Regen Res; 2025 Jan; 20(1):54-66. PubMed ID: 38767476
[TBL] [Abstract][Full Text] [Related]
50. Each big journey starts with a first step: Importance of oligomerization.
Agha MM; Aziziyan F; Uversky VN
Prog Mol Biol Transl Sci; 2024; 206():111-141. PubMed ID: 38811079
[TBL] [Abstract][Full Text] [Related]
51. Structural characterization and inhibition of toxic amyloid-β oligomeric intermediates.
Ramamoorthy A; Lim MH
Biophys J; 2013 Jul; 105(2):287-8. PubMed ID: 23870249
[No Abstract] [Full Text] [Related]
52. Suppression of mature TAU isoforms prevents Alzheimer's disease-like amyloid-beta oligomer-induced spine loss in rodent neurons.
Buchholz S; Zempel H
Neural Regen Res; 2024 Aug; 19(8):1655-1657. PubMed ID: 38103227
[No Abstract] [Full Text] [Related]
53. Retraction Note: A specific amyloid-β protein assembly in the brain impairs memory.
Lesné S; Koh MT; Kotilinek L; Kayed R; Glabe CG; Yang A; Gallagher M; Ashe KH
Nature; 2024 Jun; ():. PubMed ID: 38914864
[No Abstract] [Full Text] [Related]
54. Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons.
Um JW; Nygaard HB; Heiss JK; Kostylev MA; Stagi M; Vortmeyer A; Wisniewski T; Gunther EC; Strittmatter SM
Nat Neurosci; 2012 Sep; 15(9):1227-35. PubMed ID: 22820466
[TBL] [Abstract][Full Text] [Related]
55. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein.
Um JW; Kaufman AC; Kostylev M; Heiss JK; Stagi M; Takahashi H; Kerrisk ME; Vortmeyer A; Wisniewski T; Koleske AJ; Gunther EC; Nygaard HB; Strittmatter SM
Neuron; 2013 Sep; 79(5):887-902. PubMed ID: 24012003
[TBL] [Abstract][Full Text] [Related]
56. The prion protein as a receptor for amyloid-beta.
Kessels HW; Nguyen LN; Nabavi S; Malinow R
Nature; 2010 Aug; 466(7308):E3-4; discussion E4-5. PubMed ID: 20703260
[TBL] [Abstract][Full Text] [Related]
57. Memory impairment in transgenic Alzheimer mice requires cellular prion protein.
Gimbel DA; Nygaard HB; Coffey EE; Gunther EC; Laurén J; Gimbel ZA; Strittmatter SM
J Neurosci; 2010 May; 30(18):6367-74. PubMed ID: 20445063
[TBL] [Abstract][Full Text] [Related]
58. Interaction between human prion protein and amyloid-beta (Abeta) oligomers: role OF N-terminal residues.
Chen S; Yadav SP; Surewicz WK
J Biol Chem; 2010 Aug; 285(34):26377-83. PubMed ID: 20576610
[TBL] [Abstract][Full Text] [Related]
59. Cellular prion protein as a therapeutic target in Alzheimer's disease.
Laurén J
J Alzheimers Dis; 2014; 38(2):227-44. PubMed ID: 23948943
[TBL] [Abstract][Full Text] [Related]
60. The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease.
Larson M; Sherman MA; Amar F; Nuvolone M; Schneider JA; Bennett DA; Aguzzi A; Lesné SE
J Neurosci; 2012 Nov; 32(47):16857-71a. PubMed ID: 23175838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
